PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hangzhou Endonom Medtech Co., Ltd

USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2022–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hangzhou ranks #47,309 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.

#47,309
of 49,997 US assignees by volume
Top 28%
by Innovation Score (43.5/100)
20.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R47309 · Foreign Corporation #47,309 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #47,309/49,997
  • PHOTO-FINISH Hamilton Thorne
  • CPC-NARROW A61F · 2 areas
  • INNOV-PAR 43.5/100
  • CLAIMS-DENSE 20.6 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2022–2023 · 2y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Hamilton Thorne, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hangzhou’s 43.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Hangzhou

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Hangzhou's Innovation Score is 43.5/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Hangzhou?

Each dot is one of Hangzhou’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hangzhou’s own 20.6 claims/patent is ABOVE the 12.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Hangzhou vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 0510152025 Granted patents (volume) Avg claims / patent Hamilton Thorne, Inc. - 5, 21.4Hamilton ThorneHamlet Pharma AB - 5, 12.8Hamlet Pharma ABHandok Inc. - 5, 11.8HandokHangzhou AO KE MEI RUI Technology Co., Ltd. - 5, 18Hangzhou AO KE ME…Hangzhou Ezviz Network Co., Ltd. - 5, 1Hangzhou Ezviz Ne…Hangzhou Oxygen Plant Group Co., Ltd. - 5, 5.4Hangzhou Oxygen P…Hangzhou Xinglu Technology Co., Ltd. - 5, 19Hangzhou Xinglu T…Hanita Lenses Ltd. - 5, 18.8Hanita LensesHangzhou Endonom Medtech Co., Ltd - 5, 20.6Hangzhou Endonom…
Hangzhou vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hangzhou's grants concentrate

Hangzhou Endonom Medtech Co., Ltd is a focused PatentsView assignee: 2 CPC subclasses with 80% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2022. By volume, Hangzhou sits between Hamilton Thorne, Inc. and Hanita Lenses Ltd..

Hangzhou's three-year grant acceleration

Hangzhou Endonom Medtech Co., Ltd shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Hangzhou's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Hangzhou holds 5 patents at rank #47,303, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Hangzhou

By rank, the assignees closest to #47,303 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Hangzhou's primary technology class.

Hangzhou's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20222023 4
USPTO utility patent grants by year · 2022–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table
Hangzhou Endonom Medtech Co., Ltd patent grants by year, 2015–2025
Year Patents Granted Share of Period
2022 1 20.0%
2023 4 80.0%

Which technologies does Hangzhou Endonom Medtech Co., Ltd patent most?

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hangzhou Endonom Medtech Co., Ltd's patent record in context - here's where to go next.

  • Hangzhou Endonom Medtech Co., Ltd's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 80% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #47,309 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Hangzhou Endonom Medtech Co., Ltd against Hamilton Thorne, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 43.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.